期刊
ONCOTARGETS AND THERAPY
卷 10, 期 -, 页码 3187-3192出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S139718
关键词
lung cancer; ALK; crizotinib; small-cell lung cancer
资金
- Zhejiang Province of China [2013KYB051]
- Zhejiang Administration of Traditional Chinese Medicine Foundation [2013ZQ005]
- Science and Technology Planning Project of Zhejiang Province [2015C33194]
- National Clinical Key Specialty Construction Program
Anaplastic lymphoma kinase (ALK) rearrangement responds to ALK tyrosine kinase inhibitors (TKIs) in lung cancer. Many cases ultimately acquire resistance to crizotinib. Resistance, including ALK-dominant or ALK non-dominant, mechanisms have been described. Transformation to small-cell lung cancer is rare. Herein, we report a 49-year-old man diagnosed with adenocarcinoma, who was negative for EGFR and ALK genes as detected by reverse transcription polymerase chain reaction, and was treated with crizotinib. A new biopsy showed a small-cell lung cancer after disease progression. Then, next-generation sequencing (NGS) was carried out and detected a TP53 gene mutation, an ALK rearrangement, and no loss of the retinoblastoma gene (RB). Although a regimen for small-cell lung cancer may be one treatment option, a heterogeneous tumor may exist at the time of diagnosis and manifest during the course of disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据